Search

Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.

Read more

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia

European Hematology Association (EHA) and European Society for Medical Oncology (ESMO) agreed to collaborate on the production of European Guidelines for different hematological malignancies.

Read more

Selected EMA news

Most of EHA’s regulatory activities focus on collaboration with the European Medicines Agency (EMA).

Read more

EHA25 Virtual | News Room

Welcome to the news room of EHA25 Virtual where you can find the most relevant news items.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more

EHA-Balkan Hematology Day 2021

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 2nd edition of the EHA-Balkan Hematology Day.

Read more